Abstract:
Bicycloheptane substituted amide prostaglandin analogs are provided having the structural formula ##STR1## wherein m is 0 to 4; A is --CH. dbd. CH-- or --CH. sub. 2 --CH. sub. 2 --; n is 1 to 5; Q is --CH. dbd. CH--, --CH. sub. 2 --, ##STR2## or a single bond; R is CO. sub. 2 H, CO. sub. 2 alkyl, CO. sub. 2 alkali metal, CO. sub. 2 polyhydroxyamine salt, --CH. sub. 2 OH, ##STR3## wherein R. sup. 4 and R. sup. 5 are the same or different and are H, lower alkyl, hydroxy, lower alkoxy or aryl, at least one of R. sup. 4 and R. sup. 5 being other than hydroxy and lower alkoxy; p is 1 to 4; R. sup. 1 is H or lower alkyl; q is 1 to 12; R. sup. 2 is H or lower alkyl; and R. sup. 3 is H, lower alkyl, lower alkenyl, lower alkynyl, aryl, arylalkyl, lower alkoxy, aryloxy, arylalkyloxy, amino, alkylamino arylamino, arylalkylamino, lower alkyl-S-, aryl-S-, arylalkyl-S-, ##STR4## (wherein n' is 0, 1 or 2), alkylaminoalkyl, arylaminoalkyl, arylalkylaminoalkyl, alkoxyalkyl, aryloxyalkyl or arylalkoxyalkyl. The compounds are cardiovascular agents useful, for example, in the treatment of thrombotic disease.